A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.

NCT00503425 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

215

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: Rituximab [MabThera/Rituxan]

Sponsor

Hoffmann-La Roche